CD274 and neoplasm: However, when used as combination therapy including different substance classes, the combination of atezolizumab (PD-L1 antibody) plus bevacizumab (VEGF antibody) showed significantly improved overall survival (OS), progression-free survival (PFS), and excellent tumor response in the phase III IMBRAVE-150 study [16,17].